[Prognostic value of anemia for patients with cervical cancer treated with irradiation].
The objective of this study was to evaluate the prognostic value of anemia in uterine cervical carcinoma patients treated with irradiation.


METHODS
A total of 162 patients diagnosed with stage IIA-IIIB cervical carcinoma by the criteria of International Federation of Gynecology and Obstetrics and treated with irradiation were analyzed. Univariate and multivariate analyses using the Cox regression model were performed to determine statistical significance of some tumor-related factors. Patients were divided into two groups according to the hemoglobin level before treatment: <120 g/l (68 patients) and > or =120 g/l (94 patients).


RESULTS
In univariate analysis, the hemoglobin level before treatment showed a significant influence on overall survival (p=0.000), disease-free survival (p=0.003), local relapse-free survival (p=0.002). Lymph node status (>10 mm) assessed by computed tomography had impact on overall survival (p=0.008), disease-free survival (p=0.023) and relapse-free survival (p=0.028). Using multivariate analysis, the hemoglobin level before treatment was found to be an independent prognostic factor for overall survival (p=0.001), disease-free survival (p=0.040) and local relapse-free survival (p=0.013); lymph node status assessed by computed tomography had impact on overall survival (p=0.030) and local relapse-free survival (p=0.038).


CONCLUSIONS
Hemoglobin level before treatment is a significant prognostic factor for patients with uterine cervical carcinoma treated with irradiation.
Grigiene
Rūta
R
Institute of Oncology, Vilnius University, Lithuania. ruta@loc.lt
Aleknavicius
Eduardas
E
Kurtinaitis
Juozas
J
D000230:Adenocarcinoma / Q000097:blood / Q000000981:diagnostic imaging / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000175:diagnosis; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000000981:diagnostic imaging / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy*; D002584:Cervix Uteri / Q000473:pathology; D015331:Cohort Studies; D003627:Data Interpretation, Statistical; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy*
D006454:Hemoglobins